查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1787194

全球多種癌症早期檢測市場

Multi Cancer Early Detection
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 214 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球多種癌症早期檢測市場規模將達到 26 億美元

全球多重癌症早期檢測市場規模預計在2024年為11億美元，預計到2030年將達到26億美元，在2024-2030年的分析期內，複合年成長率為15.6%。基因檢測面板及液體切片（LDT）是本報告分析的細分市場之一，預計其複合年成長率為13.8%，到分析期結束時將達到14億美元。液態切片細分市場在分析期間的複合年成長率預計為18.2%。

美國市場規模估計為 2.96 億美元，中國市場預計複合年成長率為 20.4%

美國多種癌症早期檢測市場規模預計在2024年達到2.96億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到5.568億美元，在2024-2030年的分析期間內，複合年成長率為20.4%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為11.7%和13.9%。在歐洲，預計德國市場的複合年成長率約為12.4%。

全球多種癌症早期檢測市場—主要趨勢與促進因素摘要

多種癌症的早期檢測如何重塑癌症診斷？

多種癌症早期檢測 (MCED) 的出現正在徹底改變癌症檢測格局，這是一項突破性的技術，正在徹底改變癌症診斷。與傳統的癌症篩檢測試（例如乳癌的乳癌X 光檢查和結直腸癌的大腸鏡檢查）不同，這些測試僅針對特定數量的惡性腫瘤，而 MCED 測試利用先進的基因組、表觀基因和蛋白質組生物標記，可在單次測試中同時檢測多種癌症類型。這是透過液態切片來實現的，該液體活體組織切片分析血液樣本中的循環腫瘤 DNA (ctDNA)、RNA 特徵和其他分子變異。癌症仍然是全球最大的死亡原因，因此早期發現對於提高存活率至關重要。根據世界衛生組織 (WHO) 的數據，晚期診斷佔癌症相關死亡的很大一部分，凸顯了對早期、非侵入性和全面篩檢解決方案的迫切需求。隨著人工智慧 (AI) 和機器學習 (ML) 演算法增強生物標記識別，MCED 測試現在比以往任何時候都更加準確、擴充性且易於存取。多家生物技術公司和研究機構已透過大規模臨床試驗檢驗這些檢測方法，並取得了顯著進展，證明了在癌症症狀出現前識別癌症的潛力。這些方法有望減輕晚期癌症診斷負擔，並改善患者預後，這在醫學界、投資者和監管機構中引起了前所未有的興奮。

液態切片和人工智慧將在推進 MCED 方面發揮什麼作用？

MCED 技術的核心是液態切片與人工智慧的融合。這兩項創新技術顯著提高了多重篩檢的準確性和效率。傳統的組織切片檢查雖然有效，但具有侵入性、成本高，並且通常僅限於特定的癌症類型。相較之下，液態生物檢體侵入性極小，可以透過識別篩檢中的腫瘤衍生基因片段來檢測多種癌症。這項技術對於檢測難以篩檢的癌症尤其有價值，例如胰腺癌、卵巢和食道癌，這些癌症通常直到晚期才被診斷出來。基於人工智慧的模式識別透過快速分析海量遺傳、蛋白質組學和代謝標記資料集來區分良性和惡性訊號，進一步增強了 MCED 的功能。基於數百萬患者樣本訓練的人工智慧模型提高了診斷準確性，最大限度地減少了假陽性和假陰性，甚至可以預測檢測到的癌症的來源組織。人工智慧在MCED領域的日益普及也促進了持續學習，演算法不斷演進，以識別新的癌症亞型並適應新的分子發現。尤其是GRAIL、Guardant Health和Exact Sciences等公司，在人工智慧液態切片活體組織切片的商業化方面處於領先地位，其有效性已得到廣泛的臨床檢驗。此外，監管機構的核准，例如美國食品藥物管理局(FDA)授予領先的MCED檢測突破性認證，標誌著我們癌症篩檢方式的模式轉移。隨著這些技術的成熟，它們與常規健康檢查的整合有望成為預防醫學的新標準，將早期檢測轉變為一種經濟有效的救生策略。

醫療保健政策和市場投資如何加速 MCED 的採用？

政府政策、醫療基礎設施和投資趨勢在塑造 MCED 市場應用軌跡方面發揮關鍵作用。隨著世界各地的醫療保健系統努力應對晚期癌症治療的經濟負擔，人們越來越認同早期檢測策略的成本效益。多個國家的醫療保健組織和保險公司正在探索 MCED 檢測的報銷模式，認知到其在提高患者生存率同時降低整體癌症治療成本的潛力。例如在美國，醫療保險多癌症早期檢測篩檢覆蓋法案等立法措施旨在擴大高風險族群獲得 MCED 診斷的機會。同樣，歐盟委員會的癌症計劃優先考慮早期檢測工作，並促進將液態切片的篩檢納入國家醫療保健計劃。除了政策主導的舉措外，創業投資和私募股權投資湧入 MCED 領域也有助於加速技術進步和市場擴張。根據行業報告，過去五年來，開發 MCED 解決方案的精準腫瘤學新興企業獲得的資金大幅成長，數十億美元的估值反映出投資者對該技術顛覆性潛力的信心。大型製藥企業也正在與生技公司建立策略聯盟，共同開發和商業化 MCED 產品，進一步推動研究和創新。然而，儘管存在這些積極趨勢，監管標準化、檢測可負擔性和公眾認知等挑戰仍然是大規模應用的障礙。透過產業相關人員、政策制定者和醫療保健提供者之間的協作努力來克服這些障礙，對於確保 MCED 成為廣泛且公平的早期癌症檢測解決方案至關重要。

哪些市場促進因素正在塑造 MCED 的未來？

全球多重癌症早期檢測市場的成長受到多種因素的推動，包括技術的快速進步、精準醫療的日益普及以及全球癌症負擔的不斷增加。次世代定序(NGS) 和數位 PCR 的技術突破顯著提高了 MCED 檢測的敏感度和特異性，增強了早期癌症檢測的可靠性。人工智慧和巨量資料分析與診斷工作流程的整合也簡化了生物標記的發現，從而能夠快速且準確地識別癌症特徵。此外，個人化醫療（根據個人基因圖譜客製化治療和篩檢）的趨勢正在推動對先進 MCED 解決方案的需求。消費行為也是一個關鍵促進因素，因為人們越來越意識到早期癌症檢測的益處，患者正在尋求積極主動的醫療保健選擇。直接面對消費者 (DTC) 的基因檢測日益普及也促進了市場擴張，個人選擇 MCED 檢測作為其個人化健康監測策略的一部分。從最終用途的角度來看，醫院、診斷實驗室和研究機構是 MCED 技術的主要採用者，將這些檢測納入其常規癌症篩檢計畫。 MCED 的應用範圍不斷擴大，不僅限於腫瘤學，例如伴隨診斷和治療監測，這進一步拓寬了市場機會。此外，政府為降低癌症死亡率所做的努力正在推動支持採用 MCED 的政策框架。此外，由於醫療基礎設施的改善和可支配收入的增加，新興國家對先進診斷的需求激增。雖然市場預計會成長，但為了維持長期採用，必須解決監管的複雜性、圍繞基因檢測的倫理考量以及大規模檢驗研究的需求等挑戰。儘管如此，隨著技術創新不斷突破極限，MCED 有望成為未來癌症預防和早期療育的基石。

部分

類型（基因面板和 LDT、液態切片）、最終用途（醫院、研究、其他）

受訪公司範例

  • AnPac Bio-Medical Science Co., Ltd.
  • Becton, Dickinson and Company（BD）
  • Biocept, Inc.
  • Burning Rock Biotech Limited
  • Delfi Diagnostics, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Lucence Diagnostics Pte Ltd
  • Natera, Inc.
  • Oncimmune Holdings plc
  • Prenetics Global Limited
  • Qiagen NV
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

人工智慧整合

全球產業分析師利用可操作的專家內容和人工智慧工具改變市場和競爭情報。

我們沒有依賴典型的 LLM 或產業專用的SLM查詢，而是建立了一個由來自世界各地的領域專家精心挑選的集中內容存儲庫，其中包括影片記錄、BLOG、搜尋引擎研究以及大量的公司、產品、服務和市場數據。

關稅影響係數

我們根據公司總部所在國家、製造地和進出口（成品和OEM）情況預測其競爭地位的變化。這種複雜多變的市場動態預計將對競爭對手產生影響，包括銷貨成本成本（COGS）上升、盈利下降、供應鏈重組等微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 競賽

簡介目錄
Product Code: MCP32245

Global Multi Cancer Early Detection Market to Reach US$2.6 Billion by 2030

The global market for Multi Cancer Early Detection estimated at US$1.1 Billion in the year 2024, is expected to reach US$2.6 Billion by 2030, growing at a CAGR of 15.6% over the analysis period 2024-2030. Gene Panel & LDT, one of the segments analyzed in the report, is expected to record a 13.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Liquid Biopsy segment is estimated at 18.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$296.0 Million While China is Forecast to Grow at 20.4% CAGR

The Multi Cancer Early Detection market in the U.S. is estimated at US$296.0 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$556.8 Million by the year 2030 trailing a CAGR of 20.4% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 11.7% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.4% CAGR.

Global Multi-Cancer Early Detection Market - Key Trends & Drivers Summarized

How is Multi-Cancer Early Detection Reshaping Oncology Diagnostics?

The landscape of cancer detection is undergoing a seismic shift with the advent of Multi-Cancer Early Detection (MCED) technologies, a breakthrough that promises to revolutionize oncology diagnostics. Unlike conventional cancer screenings that target only a handful of malignancies-such as mammograms for breast cancer or colonoscopies for colorectal cancer-MCED tests utilize advanced genomic, epigenomic, and proteomic biomarkers to simultaneously detect multiple cancer types in a single assay. This is achieved through liquid biopsies, which analyze circulating tumor DNA (ctDNA), RNA signatures, and other molecular alterations in blood samples. As cancer remains a leading global cause of mortality, early detection is critical to improving survival rates. According to the World Health Organization (WHO), late-stage diagnoses account for a substantial proportion of cancer-related deaths, highlighting the urgent need for early, non-invasive, and comprehensive screening solutions. With artificial intelligence (AI) and machine learning (ML) algorithms enhancing biomarker identification, MCED tests are now more accurate, scalable, and accessible than ever before. Several biotech firms and research institutions have made significant strides in validating these tests through large-scale clinical trials, demonstrating their potential to identify cancers even before symptoms appear. The promise of reducing the burden of late-stage cancer diagnoses and improving patient outcomes has generated unprecedented excitement in the medical community, investors, and regulatory agencies alike.

What Role Do Liquid Biopsies and AI Play in Advancing MCED?

At the core of MCED technology lies the integration of liquid biopsies and artificial intelligence, two game-changing innovations that have significantly elevated the accuracy and efficiency of multi-cancer screening. Traditional tissue biopsies, while effective, are often invasive, expensive, and limited to specific cancer types. Liquid biopsies, in contrast, offer a minimally invasive alternative that can detect a broad spectrum of cancers by identifying tumor-derived genetic fragments in the bloodstream. This technique has been particularly beneficial in detecting hard-to-screen cancers, such as pancreatic, ovarian, and esophageal malignancies, which often remain undiagnosed until advanced stages. AI-driven pattern recognition further amplifies the power of MCED by rapidly analyzing vast datasets of genetic, proteomic, and metabolic markers to differentiate between benign and malignant signals. AI models trained on millions of patient samples can refine diagnostic accuracy, minimize false positives and negatives, and even predict the tissue of origin for detected cancers. The growing adoption of AI in MCED has also enabled continuous learning, where algorithms evolve to recognize emerging cancer subtypes and adapt to new molecular discoveries. Notably, companies such as GRAIL, Guardant Health, and Exact Sciences have spearheaded efforts in commercializing AI-powered liquid biopsy tests, with extensive clinical validation backing their efficacy. Furthermore, regulatory approvals, such as the breakthrough designation granted by the U.S. Food and Drug Administration (FDA) for leading MCED tests, signal a paradigm shift in how cancer screening is approached. As these technologies mature, their integration into routine health check-ups is expected to become a new standard in preventive medicine, transforming early detection into a cost-effective, life-saving strategy.

How Are Healthcare Policies and Market Investments Accelerating MCED Adoption?

Government policies, healthcare infrastructure, and investment trends play a pivotal role in shaping the trajectory of MCED market adoption. As healthcare systems worldwide grapple with the economic burden of late-stage cancer treatments, there is growing consensus on the cost-effectiveness of early detection strategies. Several national health agencies and insurance providers are exploring reimbursement models for MCED tests, acknowledging their potential to reduce overall cancer treatment costs while improving patient survival rates. In the United States, for instance, legislative efforts such as the Medicare Multi-Cancer Early Detection Screening Coverage Act aim to expand access to MCED diagnostics among high-risk populations. Similarly, the European Commission’s Cancer Plan has prioritized early detection initiatives, pushing for greater integration of liquid biopsy-based screenings into national healthcare programs. Beyond policy-driven efforts, the influx of venture capital and private equity investments in the MCED sector has been instrumental in accelerating technological advancements and market expansion. According to industry reports, funding for precision oncology startups developing MCED solutions has surged dramatically over the past five years, with multi-billion-dollar valuations reflecting investor confidence in the technology’s disruptive potential. Leading pharmaceutical giants have also entered strategic partnerships with biotech firms to co-develop and commercialize MCED products, further fueling research and innovation. However, despite these positive trends, challenges such as regulatory standardization, test affordability, and public awareness remain barriers to mass adoption. Addressing these hurdles through collaborative efforts between industry stakeholders, policymakers, and healthcare providers will be crucial in ensuring MCED becomes a widespread and equitable solution for early cancer detection.

What Are the Key Market Drivers Shaping the Future of MCED?

The growth in the global Multi-Cancer Early Detection market is driven by several factors, including rapid technological advancements, increasing adoption of precision medicine, and the rising burden of cancer worldwide. Technological breakthroughs in next-generation sequencing (NGS) and digital PCR have significantly enhanced the sensitivity and specificity of MCED tests, making them more reliable for early-stage cancer detection. The integration of AI and big data analytics into diagnostic workflows has also streamlined biomarker discovery, allowing for faster and more accurate identification of cancer signatures. Additionally, the shift toward personalized medicine, where treatments and screenings are tailored to individual genetic profiles, has fueled demand for advanced MCED solutions. Consumer behavior is another critical driver, as awareness about the benefits of early cancer detection grows and patients increasingly seek proactive healthcare options. The rising prevalence of direct-to-consumer (DTC) genetic testing has also contributed to market expansion, with individuals opting for MCED tests as part of their personalized health monitoring strategies. From an end-use perspective, hospitals, diagnostic laboratories, and research institutions are among the key adopters of MCED technologies, integrating these tests into routine cancer screening programs. The expanding applications of MCED beyond oncology-such as in companion diagnostics and treatment monitoring-have further broadened market opportunities. Additionally, government initiatives aimed at reducing cancer mortality rates have driven policy frameworks that support MCED adoption. Emerging economies are also witnessing a surge in demand for advanced diagnostics, fueled by improving healthcare infrastructure and increasing disposable incomes. While market growth is promising, challenges such as regulatory complexities, ethical considerations surrounding genetic testing, and the need for large-scale validation studies must be addressed to sustain long-term adoption. Nevertheless, as innovation continues to push boundaries, MCED is poised to become a cornerstone in the future of cancer prevention and early intervention.

SCOPE OF STUDY:

The report analyzes the Multi Cancer Early Detection market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Gene Panel & LDT, Liquid Biopsy); End-Use (Hospitals End-Use, Diagnostic Laboratories End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 48 Featured) -

  • AnPac Bio-Medical Science Co., Ltd.
  • Becton, Dickinson and Company (BD)
  • Biocept, Inc.
  • Burning Rock Biotech Limited
  • Delfi Diagnostics, Inc.
  • Epigenomics AG
  • Exact Sciences Corporation
  • Freenome Holdings, Inc.
  • GRAIL, Inc.
  • Guardant Health, Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Lucence Diagnostics Pte Ltd
  • Natera, Inc.
  • Oncimmune Holdings plc
  • Prenetics Global Limited
  • Qiagen N.V.
  • Roche Diagnostics
  • Siemens Healthineers
  • Thermo Fisher Scientific Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Multi Cancer Early Detection - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Increasing Global Cancer Prevalence Drives Accelerated Demand for Early Detection Technologies
    • Growing Investment in Liquid Biopsy and Non-invasive Testing Expands Market Opportunities for Multi Cancer Early Detection
    • Advances in Molecular Diagnostics and AI-driven Algorithms Propel Growth in Multi Cancer Early Detection Solutions
    • Rising Demand for Personalized Healthcare Solutions Strengthens the Business Case for Multi Cancer Early Detection
    • Surge in Preventive Healthcare Initiatives and Early Screening Programs Stimulates Adoption of Multi Cancer Detection Technologies
    • Regulatory Support and Approvals for Multi Cancer Early Detection Tests Expand Market Reach
    • Increasing Consumer Awareness of Cancer Risk Factors and Early Detection Benefits Accelerates Market Adoption
    • Technological Advancements in Biomarker Discovery Enhance the Sensitivity and Accuracy of Multi Cancer Early Detection Tests
    • Rising Focus on Minimally Invasive Diagnostic Methods Drives Demand for Multi Cancer Detection Solutions
    • The Expansion of Cancer Screening Guidelines and Reimbursement Policies Generates Growth in the Multi Cancer Early Detection Market
    • Growth in Telemedicine and Remote Healthcare Services Expands the Reach of Multi Cancer Detection Technologies in Rural Areas
    • The Rise in Targeted Cancer Therapies and Precision Medicine Strengthens Demand for Early Detection and Diagnosis Solutions
    • Increased Focus on Early Disease Intervention and Cost-effective Cancer Management Drives Adoption of Multi Cancer Early Detection
    • Surge in Government Funding for Cancer Research and Early Screening Drives Technological Advancements in Multi Cancer Detection
    • The Growing Use of Wearable Devices and Health Apps for Cancer Monitoring Expands Opportunities for Integration with Early Detection Solutions
    • The Emergence of Multi-omics Approaches in Cancer Detection Expands Market Potential for Next-generation Diagnostic Tools
    • Rising Global Cancer Awareness and Screening Initiatives in Developing Economies Boost Demand for Multi Cancer Detection Solutions
    • Strategic Partnerships Between Biotech Firms and Healthcare Providers Propel Market Growth and Innovation in Early Detection Technologies
    • The Increasing Incidence of Cancer in Younger Populations Expands the Addressable Market for Early Detection Tools
    • Growing Interest in Cancer Prevention and Early Detection for High-risk Populations Stimulates Demand for Multi Cancer Screening Tests
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multi Cancer Early Detection Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Gene Panel & LDT by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Gene Panel & LDT by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Liquid Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Liquid Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Diagnostic Laboratories End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Diagnostic Laboratories End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 14: USA Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 15: USA 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 16: USA Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 17: USA 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CANADA
    • TABLE 18: Canada Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 19: Canada 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 20: Canada Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 21: Canada 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • JAPAN
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 22: Japan Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 23: Japan 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 24: Japan Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 25: Japan 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • CHINA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 26: China Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 27: China 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 28: China Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 29: China 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • EUROPE
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 30: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 31: Europe 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 32: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Europe 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 34: Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Europe 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • FRANCE
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 36: France Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 37: France 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 38: France Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: France 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • GERMANY
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 40: Germany Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Germany 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 42: Germany Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Germany 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ITALY
    • TABLE 44: Italy Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Italy 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 46: Italy Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Italy 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED KINGDOM
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 48: UK Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 49: UK 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 50: UK Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: UK 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SPAIN
    • TABLE 52: Spain Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Spain 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 54: Spain Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Spain 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • RUSSIA
    • TABLE 56: Russia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Russia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 58: Russia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 59: Russia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 60: Rest of Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Rest of Europe 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 62: Rest of Europe Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Rest of Europe 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 64: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 65: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2025 & 2030
    • TABLE 66: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 68: Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • AUSTRALIA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 70: Australia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Australia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 72: Australia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Australia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • INDIA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 74: India Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: India 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 76: India Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 77: India 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SOUTH KOREA
    • TABLE 78: South Korea Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 79: South Korea 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 80: South Korea Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: South Korea 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 82: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 84: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Asia-Pacific 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • LATIN AMERICA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 86: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 87: Latin America 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2025 & 2030
    • TABLE 88: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Latin America 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 90: Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Latin America 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ARGENTINA
    • TABLE 92: Argentina Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Argentina 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 94: Argentina Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Argentina 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • BRAZIL
    • TABLE 96: Brazil Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Brazil 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 98: Brazil Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Brazil 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • MEXICO
    • TABLE 100: Mexico Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 101: Mexico 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 102: Mexico Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 103: Mexico 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 104: Rest of Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Latin America 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 106: Rest of Latin America Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Latin America 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • MIDDLE EAST
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 108: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 109: Middle East 6-Year Perspective for Multi Cancer Early Detection by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2025 & 2030
    • TABLE 110: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Middle East 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 112: Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Middle East 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • IRAN
    • TABLE 114: Iran Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Iran 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 116: Iran Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Iran 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • ISRAEL
    • TABLE 118: Israel Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Israel 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 120: Israel Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Israel 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • SAUDI ARABIA
    • TABLE 122: Saudi Arabia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Saudi Arabia 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 124: Saudi Arabia Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Saudi Arabia 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 126: UAE Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 127: UAE 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 128: UAE Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UAE 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 130: Rest of Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 131: Rest of Middle East 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 132: Rest of Middle East Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 133: Rest of Middle East 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030
  • AFRICA
    • Multi Cancer Early Detection Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 134: Africa Recent Past, Current & Future Analysis for Multi Cancer Early Detection by Type - Gene Panel & LDT and Liquid Biopsy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Africa 6-Year Perspective for Multi Cancer Early Detection by Type - Percentage Breakdown of Value Sales for Gene Panel & LDT and Liquid Biopsy for the Years 2025 & 2030
    • TABLE 136: Africa Recent Past, Current & Future Analysis for Multi Cancer Early Detection by End-Use - Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 137: Africa 6-Year Perspective for Multi Cancer Early Detection by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Diagnostic Laboratories End-Use and Other End-Uses for the Years 2025 & 2030

IV. COMPETITION